Oxion Biologics

Executive Summary

Oxion Biologics is a clinical-stage Swedish biotechnology company developing novel therapeutics for autoimmune and immune-mediated diseases. Its lead candidate, OX118, is a best-in-class anti-OX40L monoclonal antibody designed to rebalance the immune system by blocking the OX40-OX40L interaction, a key pathway in T-cell activation and autoimmune pathology. The company is poised to initiate first-in-human trials in 2025, targeting indications such as atopic dermatitis, asthma, and other type 2 inflammatory diseases. OX118 has shown promising preclinical results, including improved pharmacokinetics and potency compared to first-generation anti-OX40L antibodies. With a strong scientific foundation and a clear unmet need in chronic autoimmune conditions, Oxion represents an attractive early-stage opportunity in the biologics space. As a private company, Oxion has not disclosed its funding history, but it is likely to require additional capital to advance OX118 through Phase 1 development. The upcoming initiation of clinical trials is a key derisking event that could validate the preclinical promise. If successful, OX118 could compete with other anti-OX40L programs, including amlitelimab (Sanofi) and rocatinlimab (Amgen), potentially offering best-in-class efficacy and dosing convenience. The company's location in Stockholm provides access to a vibrant biotech ecosystem and potential non-dilutive funding from European sources. Investors should monitor clinical trial enrollment and early safety data as critical near-term catalysts.

Upcoming Catalysts (preview)

• Q2 2025First Patient Dosed in Phase 1 Trial90% success
• Q4 2025Phase 1 Interim Safety & PK Data75% success
• Q1 2026Series B Financing Announcement60% success